WES WHEELER, your professional success has brought great esteem to the WPI community. You are an expert in your field with unparalleled leadership abilities. The WPI Alumni Association is proud to honor you today.

Your education provided a strong foundation for your career. You graduated from WPI with a bachelor's degree in mechanical engineering, with distinction. Later, you completed your master's degree in business administration, focusing on finance, from California Lutheran University.

You began your career as a field engineer for Exxon and after 12 years transitioned to the pharmaceutical industry. You joined Glaxo at its research headquarters in Raleigh, North Carolina as director of engineering. After completing your MBA, you were promoted to vice president of marketing of GlaxoWellcome's US Operations and managed all marketing activities for the gastrointestinal, anti-infectives, HSV, and metabolic diseases business unit.

In December 1989, you were promoted to senior vice president of manufacturing and supply at GlaxoSmithKline. After the SmithKline Beecham merger, you became responsible for consolidating all manufacturing, procurement, and logistics for its 109 factories to one central division and managed a five-year transformational change program.

After 12 years with GlaxoSmithKline (GSK), you were recruited as the chief executive officer at DSM Pharmaceutical Products, based in the Netherlands. During this time, you oversaw all pharmaceutical operations at DSM in Greenville, North Carolina, a site with over 1,200 employees. It was your first turnaround role, as the site was operating under an FDA Warning Letter. You worked with the FDA to restore all operating licenses while simultaneously launching important new drugs for Amgen, Genentech, and Shire Pharmaceuticals.

In early 2003, you became president of Valeant Pharmaceuticals in Costa Mesa, California. In your five years there, you managed the North American business, all global marketing, and all acquisitions. You led the acquisition of Xcel Pharmaceuticals and the public financing effort which provided the funds. You took on additional responsibilities as president of the R&D and global manufacturing divisions and developed a novel new drug for epilepsy, which was ultimately acquired by GSK.

Those five years were seen as a major turnaround period in Valeant's history. In 2007, you were recruited as CEO of Parthenon, a leading contract manufacturer for the pharmaceutical industry. The publicly traded company operated 11 factories in five countries. You improved efficiency by closing three facilities, launching a Lean Six Sigma program and optimizing processes, while growing market share. You re-structured the entire company, brought in new leadership and moved the global headquarters to North Carolina during its transformation to a privately owned company. It is now the world's largest manufacturing service provider in the pharmaceutical industry.

In 2011, you were recruited to Marken, the only patient-centric supply chain organization 100 percent dedicated to the pharmaceutical and life sciences industries. You are currently the chief executive officer. Marken maintains the leading position for direct-to-patient services and biological sample shipments and offers state-of-the-art GMP compliant depot network and logistic hubs in 47 locations worldwide. At the end of 2016, you successfully managed a sale of the company to UPS, the world's largest transportation company and are currently in the process of integrating Marken into the company's healthcare vertical.

Wes Wheeler, you are known for your deep operational experience, your expertise as a leader, and your ability to work in different cultures. These experiences have provided you with a unique range of perspectives and skills that have allowed you to transform and grow companies all over the world. The WPI Alumni Association is pleased to recognize you today with the Robert H. Goddard Award for Outstanding Professional Achievement.